Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for pediatric patients with malignant glioma.
Not Applicable
- Conditions
- High grade glioma, Diffuse intrinsic pontine glioma
- Registration Number
- JPRN-UMIN000013257
- Lead Sponsor
- Osaka University Graduate School of Medicine Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1.There is deep-seated active infection. 2.There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis. 3.Patients who have complications that are considered inappropriate for the trial. 4.There are other malignancies. 5.There are hematopoietic stem cell disorders such as MDS. 6.Post allogeneic hematopoietic stem cell transplantation 7.Responsible doctors judged the patient inappropriate for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safty
- Secondary Outcome Measures
Name Time Method progression free survival time all over survival time Immunomonitering